Metropolis Healthcare Ltd Q2 FY2026 Concall Summary

Key Takeaways

• Organic growth steady, fever tailwind absent: Organic revenue grew 12% YoY despite a weaker monsoon-driven fever season, offset by Specialty testing and TruHealth.
• Margin expansion on track: Organic margins improved 60 bps YoY to 26.8%, in line with the full-year commitment, though Q2 is seasonally the highest-margin quarter.
• Core Diagnostics integration progressing: Core EBITDA moved from breakeven to high-single-digit this quarter, with management sticking to a high-single-digit average for FY26 and a path to double-digit next year.
• Acquisition pause signals organic focus: Management explicitly ruled out new acquisitions for 6-9 months, prioritizing integration and organic scaling of existing strategic drivers.
• What to watch next quarter: Whether Core Diagnostics margins reach higher-single-digit in seasonally weak Q3, and any update on the trajectory toward Metropolis-level margins by FY28.

Organic Performance & Seasonality

• Fever gap filled by Specialty and TruHealth: Lower incidence of chikungunya, malaria, dengue and viral fevers slowed fever-related test volume growth, but the company compensated by emphasizing higher-value Specialty testing and TruHealth wellness packages.
• B2C drives the mix: B2C contributed 59% of total revenues with 11% YoY organic growth, supported by targeted micro marketing and clinician engagement; management expects B2C contribution to be slightly higher by year-end.
• B2B cleans up and grows: B2B accounted for 41% of volumes with 14% YoY organic growth, helped by a one-quarter specific clinical trial contract and a cleaner base after cutting low-margin corporate and government business last year.
• Mumbai holds strong: Mumbai revenues grew 13% YoY despite the fever shortfall, reaffirming the company's leadership in its home market.
• Q2 margin is a seasonal high: Q2 is a relatively high-volume quarter, so margins are better than the average for the year; Q3 is usually the lowest quarter because of festivals.

Surendran Chemmenkotil: "What happens in quarter 2 is relatively a high-volume quarter, and hence, your margins will be definitely better than the average margin of the year. And hence, it's not necessary that the quarter 2 our margins will be the same going forward in quarter 3 and quarter 4."

Core Diagnostics Integration

• Margin ramp from breakeven to high-single-digit: Core Diagnostics EBITDA improved from breakeven in March to roughly 2%-3% in Q1 and mid-to-high single-digit in Q2; management declined to upgrade the full-year average from high-single-digit despite the Q2 beat.
• Path to parity takes longer than hoped: Management reiterated it will take another 2 to 2.5 years to bring Core to Metropolis-level margins of around 23%-24%, pushing the target to FY28; an analyst's suggestion of reaching parity by H1 FY27 was explicitly rejected.
• Integration still in progress: Duplicate infrastructure has been shut down and procurement and corporate cost synergies realized, but new costs like technology and audit have come in; full integration may take a couple more quarters.
• Revenue cleanup masks future growth: Revenue growth in the first six months was negatively impacted by cleanup of past practices; management frames this as setting the foundation for faster growth later.
• Year 1 efficiency, Year 2 growth: The acquisition playbook is explicit: the first year focuses on integration and efficiency, the second year on scaling revenue growth over the strengthened foundation.

Ameera Shah: "Q3, we hope to move to a higher-single-digit and then Q4 move to sort of closer to a double-digit. So the average for the year will still come out to a high-single-digit, which gives us a good foundation to make a leap into next year to obviously move into a double-digit margin on track for what we had sort of projected when we actually made the acquisition."

Industry Structure & Competitive Position

• Barrier to scale, not entry: Management argues that while the barrier to enter diagnostics is low, the barrier to scale profitably is extremely high; entrants often lose interest after 2-3 years, and the organized sector is growing faster as small independent labs struggle.
• Consolidation tailwinds by region and lab type: Technician-run labs without scale or a moat are shutting down; pathologist-run labs face succession issues; West and South likely see more consolidation than North and East; bigger cities make survival harder for smaller labs due to higher competition and compliance costs.
• No new competitive pressure: No significant new players have entered in the last couple of years, and B2B price competition has been stable for 1-2 years.
• Clinical trial niche is small but defensible: The clinical trial testing business is more structured and difficult to enter than routine lab work; Metropolis is probably the largest or number 2 player in India, but the market is not very large and every year varies with drug approval velocity.

Ameera Shah: "What people realize after spending 2, 3 years in the industry is that while the barrier to enter is low, the barrier to scale is not so low. It's actually hard. And the barrier to scale profitably is extremely high."

Strategic Initiatives: Digital, Radiology & Genomics

• Digital stack rollout underway: The company launched a new consumer app, partner app, lead automation for partners, middleware auto-authorization in labs, an enhanced inventory management system, and AI call quality monitoring in the contact centre.
• Radiology is early but expanding: Basic radiology services (ECG, X-ray, ultrasound) have been added to TruHealth packages; ECG is available nationwide, X-ray and ultrasound in around 5 towns; high-end radiology like MRI or CT scan is not planned for the rest of the year.
• Genomics built on Core's platform: Core Diagnostics has enhanced capabilities in high-end molecular diagnostics, oncology and next-generation sequencing; however, genomic tests are not offered in preventive packages because scientific data for the Indian population does not yet exist to support correct clinical decisions.
• GLP-1 opportunity on the horizon: Management sees a long-term structural opportunity to co-create testing protocols, packages and wellness-plus-disease-management pathways aligned with GLP-1-based treatments, though full-fledged availability and usage in India has not yet materialized.
• Collection centre expansion continues: Approximately 200 centres were added in H1, with another 300 planned in H2; the company now reaches 750 towns, and the first destination is to reach 30 centres per lab, likely in the next 12-18 months, mostly via franchisees.

Ameera Shah: "So by doing it from a preventive basis, doing a genetic test for a preventive basis, the data does not exist for India today that allows you to make a good correct scientific decision on the back of that."

AI: Ambition Tempered by Indian Reality

• Non-medical AI is near-term: Real use cases exist across recruitment, screening, talent onboarding, billing and accounting; the company is early in that journey and hopes to implement meaningful tools over the next year or so.
• Medical AI is years away for India: Management is explicit that AI models from the US and Europe cannot be plugged into the Indian ecosystem because Indian data sets do not exist yet; it will take a few years for those models to become relevant.
• AI as a tool, not a replacement: The company frames AI as a tool to empower doctors to make better decisions, not a tool replacing doctors; the scenario of AI replacing doctors in medical testing is described as "very hypothetical."
• Productivity roadmap runs 6-12 months: A focused roadmap on people productivity, process and lab operation efficiency through AI and digitization is underway, part of the broader Metropolis 3.0 strategy to accelerate presence in Tier 2 and Tier 3 cities while strengthening specialized testing and digital tools.

Ameera Shah: "The second part of AI, which is using AI for medical tests where you don't need doctors is a very hypothetical scenario. In our minds, AI is a tool to empower doctors to make better decisions, not a tool replacing doctors."

Guidance & Commitments

Key Metrics